A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Authors: Sabeena Ahmed 1Mohammad Mahbubul Karim 1Allen G Ross 1Mohammad Sharif Hossain 1John D Clemens 1Mariya Kibtiya Sumiya 1Ching Swe Phru 1Mustafizur Rahman 1Khalequ Zaman 1Jyoti Somani 2Rubina Yasmin 3Mohammad Abul Hasnat 4Ahmedul Kabir 5Asma Binte Aziz 1Wasif Ali Khan 6


Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virologic clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.

For More Information: https://pubmed.ncbi.nlm.nih.gov/33278625/

Leave a Reply

Your email address will not be published. Required fields are marked *